Urogen Pharma (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from Analysts

Key Points

• Urogen Pharma has received a consensus recommendation of "Buy" from nine analysts, with an average twelve-month price target of $32.00.
• Insider trading activity shows that Mark Schoenberg sold 10,000 shares at an average price of $17.69, indicating a decrease in his ownership by 6.32%.
• The company recently reported earnings of ($1.05) per share, missing the consensus estimate by ($0.23), while revenue for the quarter was $24.22 million.

Shares of Urogen Pharma (NASDAQ:URGN - Get Free Report) have earned a consensus rating of "Buy" from the nine analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $32.00.

Several equities research analysts have recently weighed in on the company. HC Wainwright decreased their price objective on Urogen Pharma from $50.00 to $40.00 and set a "buy" rating for the company in a report on Monday, August 11th. Scotiabank reissued an "outperform" rating on shares of Urogen Pharma in a report on Friday, June 13th. Wall Street Zen raised Urogen Pharma from a "sell" rating to a "hold" rating in a report on Saturday, September 13th. Oppenheimer set a $31.00 price target on Urogen Pharma and gave the stock a "buy" rating in a report on Friday, June 13th. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price target on shares of Urogen Pharma in a report on Tuesday, August 5th.

Insider Buying and Selling at Urogen Pharma

In related news, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction on Monday, August 11th. The stock was sold at an average price of $17.69, for a total transaction of $176,900.00. Following the completion of the sale, the insider directly owned 148,229 shares of the company's stock, valued at $2,622,171.01. This trade represents a 6.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Jason Drew Smith sold 1,520 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $19.11, for a total value of $29,047.20. Following the sale, the general counsel directly owned 43,305 shares of the company's stock, valued at approximately $827,558.55. This represents a 3.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 25,062 shares of company stock valued at $465,115. Corporate insiders own 4.70% of the company's stock.

Institutional Investors Weigh In On Urogen Pharma

Several hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Urogen Pharma by 9.4% during the second quarter. China Universal Asset Management Co. Ltd. now owns 9,261 shares of the company's stock worth $127,000 after purchasing an additional 797 shares during the period. Wellington Management Group LLP lifted its holdings in Urogen Pharma by 0.8% in the first quarter. Wellington Management Group LLP now owns 148,078 shares of the company's stock valued at $1,638,000 after acquiring an additional 1,125 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Urogen Pharma by 7.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company's stock valued at $258,000 after acquiring an additional 1,653 shares during the period. Main Street Financial Solutions LLC lifted its holdings in Urogen Pharma by 8.2% in the second quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company's stock valued at $356,000 after acquiring an additional 1,968 shares during the period. Finally, Rhumbline Advisers lifted its holdings in Urogen Pharma by 4.3% in the first quarter. Rhumbline Advisers now owns 53,466 shares of the company's stock valued at $591,000 after acquiring an additional 2,196 shares during the period. 91.29% of the stock is owned by institutional investors and hedge funds.

Urogen Pharma Trading Down 10.7%

URGN stock opened at $17.82 on Thursday. The company has a market capitalization of $824.35 million, a P/E ratio of -5.37 and a beta of 1.01. Urogen Pharma has a twelve month low of $3.42 and a twelve month high of $21.71. The business has a 50 day simple moving average of $19.05 and a 200-day simple moving average of $13.59.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.23). The firm had revenue of $24.22 million during the quarter, compared to analyst estimates of $23.06 million. Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. Research analysts predict that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.